The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, but its future within the broader sector now raises questions about potential returns . Generic versions are undercutting market share, leading to anxieties that investing in companies significantly dependent to Viagra's previous standing could be a speculati